Drugmaker Biogen Inc beat analysts' estimates for quarterly profit and lifted its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis therapy Tecfidera.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,